Cargando…

Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells

Differentiation induction is currently considered as an alternative strategy for treating chronic myelogenous leukemia (CML). Our previous work has demonstrated that Sprouty-related EVH1 domainprotein2 (Spred2) was involved in imatinib mediated cytotoxicity in CML cells. However, its roles in growth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yuefeng, Liu, Xiaoyun, Xiao, Fengjun, Xue, Shuya, Xu, Qinqin, Yin, Yue, Sun, Huiyan, Xu, Jie, Wang, Hengxiang, Zhang, Qunwei, Wang, Hua, Wang, Lisheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331423/ https://www.ncbi.nlm.nih.gov/pubmed/25688862 http://dx.doi.org/10.1371/journal.pone.0117573

Ejemplares similares

Spred2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by impairing ERK signaling
por: Wang, Hao, et al.
Publicado: (2020)

Methylation of SPRED1: A New Target in Acute Myeloid Leukemia
por: Su, Nan, et al.
Publicado: (2022)

SPRED1 Is Downregulated and a Prognostic Biomarker in Adult Acute Myeloid Leukemia
por: Zhang, Rui, et al.
Publicado: (2020)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation
por: Lee, Yueh-Lun, et al.
Publicado: (2013)

A Pilot Study of Aberrant CpG Island Hypermethylation of SPRED1 in Acute Myeloloid Leukemia
por: Sun, Jingwen, et al.
Publicado: (2019)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Correction: Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation
por: Lee, Yueh-Lun, et al.
Publicado: (2017)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL
por: Zhu, Li, et al.
Publicado: (2016)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia
por: Arya, Deepak, et al.
Publicado: (2017)

Surface Phosphatidylserine Is Responsible for the Internalization on Microvesicles Derived from Hypoxia-Induced Human Bone Marrow Mesenchymal Stem Cells into Human Endothelial Cells
por: Wei, Xiaojuan, et al.
Publicado: (2016)

Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR
por: Yan, Wupeng, et al.
Publicado: (2020)

CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia
por: Zhang, Tianzhuo, et al.
Publicado: (2020)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL
por: Wang, Tao, et al.
Publicado: (2019)

MicroRNA-181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib
por: WANG, GUANGYU, et al.
Publicado: (2015)

Pure erythroid leukemia
por: Chen, Jason C., et al.
Publicado: (2020)

Pure erythroid leukemia
por: Forest, Méghan, et al.
Publicado: (2020)

The SPRED1 Variants Repository for Legius Syndrome
por: Sumner, Kelli, et al.
Publicado: (2011)

Progress in experimental research on SPRED protein family
por: Gong, Jian, et al.
Publicado: (2020)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib
por: Nie, Danian, et al.
Publicado: (2018)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
por: Bitencourt, Roberta, et al.
Publicado: (2011)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
por: Scerni, Ana Carolina Costa, et al.
Publicado: (2009)

Gynecomastia in a Boy with Chronic Myeloid Leukemia during Imatinib Therapy
por: Tavil, Betül, et al.
Publicado: (2013)

Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment
por: Angriman, Federico, et al.
Publicado: (2015)

Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female
por: Agrawal, Prabhat, et al.
Publicado: (2015)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_67b804v8h0op31ghtbo58qkn11